ENHANCED DELIVERY OF GANCICLOVIR TO THE BRAIN THROUGH THE USE OF REDOX TARGETING

被引:43
作者
BREWSTER, ME [1 ]
RAGHAVAN, K [1 ]
POP, E [1 ]
BODOR, N [1 ]
机构
[1] UNIV FLORIDA, J HILLIS MILLER HLTH CTR, COLL PHARM, CTR DRUG DISCOVERY, GAINESVILLE, FL 32610 USA
关键词
D O I
10.1128/AAC.38.4.817
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Enhanced delivery of ganciclovir to the brain was demonstrated by a redox-based chemical delivery system. A ganciclovir monoester in which a 1-methyl-1,4-dihydronicotinate was covalently attached to one of the hydroxymethyl functions was prepared. The stability of the ganciclovir chemical delivery system (DHPG-CDS) was evaluated in aqueous buffers and organ homogenates. In vivo distribution studies in the rat indicated that while ganciclovir poorly penetrated into the central nervous system and was rapidly eliminated, DHPG-CDS provided for therapeutically relevant (2.7 muM) and sustained levels of the parent compound through 6 h. An analysis of the area under the concentration curve indicated that the chemical delivery system delivered five times more ganciclovir than that of the parent drug. The high levels in the brain and reduced levels in the blood gave a brain-to-blood drug concentration ratio of 2.54 for ganciclovir when delivered by the chemical delivery system, compared to a ratio of 0.063 when the parent drug was administered. These data suggest that DHPG-CDS. could be a useful adjunct for the treatment of cytomegalovirus encephalitis.
引用
收藏
页码:817 / 823
页数:7
相关论文
共 38 条
  • [31] PALESTINE AG, 1988, REV INFECT DIS, V10, pS515
  • [32] CHEMICAL AND ENZYMATIC DEGRADATION OF GANCICLOVIR PRODRUGS - ENHANCED STABILITY OF THE DIADAMANTOATE PRODRUG UNDER ACID CONDITIONS
    POWELL, MF
    MAGILL, A
    CHU, N
    HAMA, K
    MAU, CI
    FOSTER, L
    BERGSTROM, R
    [J]. PHARMACEUTICAL RESEARCH, 1991, 8 (11) : 1418 - 1423
  • [33] HERPESVIRUS INFECTIONS IN THE ACQUIRED IMMUNE-DEFICIENCY SYNDROME
    QUINNAN, GV
    MASUR, H
    ROOK, AH
    ARMSTRONG, G
    FREDERICK, WR
    EPSTEIN, J
    MANISCHEWITZ, JF
    MACHER, AM
    JACKSON, L
    AMES, J
    SMITH, HA
    PARKER, M
    PEARSON, GR
    PARRILLO, J
    MITCHELL, C
    STRAUS, SE
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1984, 252 (01): : 72 - 77
  • [34] ACTIVITY OF 9-[2-HYDROXY-1-(HYDROXYMETHYL)ETHOXYMETHYL]GUANINE IN THE TREATMENT OF CYTOMEGALO-VIRUS PNEUMONIA
    SHEPP, DH
    DANDLIKER, PS
    DEMIRANDA, P
    BURNETTE, TC
    CEDERBERG, DM
    KIRK, LE
    MEYERS, JD
    [J]. ANNALS OF INTERNAL MEDICINE, 1985, 103 (03) : 368 - 373
  • [35] NEUROLOGICAL COMPLICATIONS OF ACQUIRED IMMUNE-DEFICIENCY SYNDROME - ANALYSIS OF 50 PATIENTS
    SNIDER, WD
    SIMPSON, DM
    NIELSEN, S
    GOLD, JWM
    METROKA, CE
    POSNER, JB
    [J]. ANNALS OF NEUROLOGY, 1983, 14 (04) : 403 - 418
  • [36] PRODRUGS AND SITE-SPECIFIC DRUG DELIVERY
    STELLA, VJ
    HIMMELSTEIN, KJ
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1980, 23 (12) : 1276 - 1282
  • [37] WINKELMANN E, 1988, ARZNEIMITTELFORSCH, V38-2, P1545
  • [38] ANTIVIRAL ACTIVITY AND PHARMACOKINETICS OF HOE 602, AN ACYCLIC NUCLEOSIDE, IN ANIMAL-MODELS
    WINKLER, I
    WINKELMANN, E
    SCHOLL, T
    ROSNER, M
    JAHNE, G
    HELSBERG, M
    [J]. ANTIVIRAL RESEARCH, 1990, 14 (02) : 61 - 73